Liu Xiaoyang
Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
Front Immunol. 2025 Mar 5;16:1520968. doi: 10.3389/fimmu.2025.1520968. eCollection 2025.
Dengue virus (DENV) is a mosquito-borne virus with a significant human health concern. With 390 million infections annually and 96 million showing clinical symptoms, severe dengue can lead to life-threatening conditions like dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The only FDA-approved vaccine, Dengvaxia, has limitations due to antibody-dependent enhancement (ADE), necessitating careful administration. The recent pre-approval of TAK-003 by WHO in 2024 highlights ongoing efforts to improve vaccine options. This review explores recent advancements in dengue vaccine development, emphasizing potential utility of mRNA-based vaccines. By examining current clinical trial data and innovations, we aim to identify promising strategies to address the limitations of existing vaccines and enhance global dengue prevention efforts.
登革病毒（DENV）是一种通过蚊子传播的病毒，对人类健康构成重大威胁。每年有3.9亿人感染，9600万人出现临床症状，严重登革热可导致危及生命的情况，如登革出血热（DHF）和登革休克综合征（DSS）。唯一获得美国食品药品监督管理局（FDA）批准的疫苗登革热疫苗（Dengvaxia）由于抗体依赖增强（ADE）存在局限性，因此需要谨慎接种。世界卫生组织（WHO）于2024年对TAK - 003的近期预批准凸显了在改善疫苗选择方面的持续努力。本综述探讨了登革热疫苗研发的最新进展，强调了基于mRNA的疫苗的潜在效用。通过研究当前的临床试验数据和创新成果，我们旨在确定有前景的策略，以解决现有疫苗的局限性并加强全球登革热预防工作。
